INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 222 filers reported holding INOVIO PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 1.02 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $321,768 | -40.5% | 392,400 | +13.2% | 0.00% | – |
| Q4 2022 | $540,696 | +11.7% | 346,600 | +23.6% | 0.00% | – |
| Q3 2022 | $484,000 | -0.2% | 280,400 | 0.0% | 0.00% | – |
| Q2 2022 | $485,000 | -51.8% | 280,400 | 0.0% | 0.00% | – |
| Q1 2022 | $1,007,000 | -57.9% | 280,400 | -41.5% | 0.00% | -100.0% |
| Q4 2021 | $2,393,000 | +19.6% | 479,500 | +71.6% | 0.00% | 0.0% |
| Q3 2021 | $2,001,000 | -31.4% | 279,500 | -11.1% | 0.00% | 0.0% |
| Q2 2021 | $2,915,000 | +43.5% | 314,500 | +43.7% | 0.00% | 0.0% |
| Q1 2021 | $2,031,000 | +6.9% | 218,900 | +2.0% | 0.00% | 0.0% |
| Q4 2020 | $1,900,000 | -23.7% | 214,700 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $2,491,000 | -64.4% | 214,700 | -17.4% | 0.00% | -75.0% |
| Q2 2020 | $7,002,000 | +665.2% | 259,830 | +111.2% | 0.00% | +300.0% |
| Q1 2020 | $915,000 | +67.9% | 123,000 | -25.5% | 0.00% | – |
| Q4 2019 | $545,000 | +61.2% | 165,000 | 0.0% | 0.00% | – |
| Q3 2019 | $338,000 | -30.3% | 165,000 | 0.0% | 0.00% | – |
| Q2 2019 | $485,000 | +8.7% | 165,000 | +37.8% | 0.00% | – |
| Q1 2019 | $446,000 | -9.2% | 119,700 | -2.5% | 0.00% | – |
| Q4 2018 | $491,000 | -22.3% | 122,800 | +8.0% | 0.00% | – |
| Q3 2018 | $632,000 | +33.6% | 113,700 | -5.7% | 0.00% | – |
| Q2 2018 | $473,000 | -3.1% | 120,600 | +16.4% | 0.00% | – |
| Q1 2018 | $488,000 | +39.0% | 103,600 | +21.7% | 0.00% | – |
| Q4 2017 | $351,000 | -35.0% | 85,100 | 0.0% | 0.00% | – |
| Q3 2017 | $540,000 | -27.9% | 85,100 | -10.9% | 0.00% | -100.0% |
| Q2 2017 | $749,000 | +46.9% | 95,500 | +23.9% | 0.00% | – |
| Q1 2017 | $510,000 | -23.1% | 77,100 | -19.4% | 0.00% | -100.0% |
| Q4 2016 | $663,000 | -25.6% | 95,600 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $891,000 | +0.9% | 95,600 | 0.0% | 0.00% | 0.0% |
| Q2 2016 | $883,000 | +42.6% | 95,600 | +34.5% | 0.00% | 0.0% |
| Q1 2016 | $619,000 | +11.9% | 71,100 | -13.6% | 0.00% | – |
| Q4 2015 | $553,000 | +16.2% | 82,300 | 0.0% | 0.00% | – |
| Q3 2015 | $476,000 | -29.2% | 82,300 | 0.0% | 0.00% | -100.0% |
| Q2 2015 | $672,000 | 0.0% | 82,300 | 0.0% | 0.00% | 0.0% |
| Q1 2015 | $672,000 | -11.1% | 82,300 | 0.0% | 0.00% | 0.0% |
| Q4 2014 | $756,000 | -8.7% | 82,300 | -2.1% | 0.00% | 0.0% |
| Q3 2014 | $828,000 | -8.9% | 84,100 | 0.0% | 0.00% | 0.0% |
| Q2 2014 | $909,000 | – | 84,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON ASSOCIATES LP | 784,679 | $643,437 | 0.10% |
| Green Alpha Advisors, LLC | 146,300 | $119,966 | 0.08% |
| Virtus ETF Advisers LLC | 54,106 | $44,367 | 0.02% |
| Cedar Brook Financial Partners, LLC | 104,881 | $86,002 | 0.02% |
| PROFUND ADVISORS LLC | 418,749 | $343,374 | 0.02% |
| Arlington Capital Management, Inc. | 27,735 | $22,743 | 0.02% |
| Hennion & Walsh Asset Management, Inc. | 382,158 | $313 | 0.02% |
| Rafferty Asset Management, LLC | 2,647,927 | $2,171,300 | 0.02% |
| Brainard Capital Management LLC | 16,666 | $13,666 | 0.01% |
| Beck Bode, LLC | 41,218 | $33,799 | 0.01% |